A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review

Abstract

<b><i>Background:</i></b> Sodium-glucose cotransport protein 2 (SGLT2) inhibitors, a new type of glucose-lowering drug, have been well proved in several clinical studies for their glucose-lowering and nephroprotective effects, and the nephroprotective effects include both indirect effects of metabolic improvement and direct effects, independent of glucose-lowering effects. <b><i>Summary:</i></b> In patients with diabetic kidney disease (DKD), several studies have demonstrated the potential nephroprotective mechanisms of SGLT2 inhibitors, and evidence of nephroprotective mechanisms in the non-DKD population is accumulating. Although the nephroprotective mechanism of SGLT2 inhibitors has not been fully elucidated, several laboratory studies have illustrated the mechanism underlying the effects of SGLT2 inhibitors at various aspects. <b><i>Key Messages:</i></b> The purpose of this article is to review the mechanism of nephroprotective effect of SGLT2 inhibitors and to look forward to promising research in the future.

Comité de Gerontología. Abordaje clínico terapéutico del adulto mayor con diabetes mellitus

“…En casos especiales, como comorbilidad cardiovascular severa o renal incipiente, vale pensar en SLGT-2 o análogos de GLP-1 que también son beneficiosos en caso de deterioro cognitivo y obesidad mórbida. Sin embargo, hay que considerar los efectos colaterales, costo, repercusión hemodinámica, pancreatitis, caídas, fracturas, internaciones, casos de depresión y mortalidad, especialmente en mayores de 75 años 8,[27][28][29][30][31][32] .…”

“…Revista de la Sociedad Argentina de Diabetes 2024; Vol. 58 (28)(29)(30)(31)(32) The development of civilization is associated with an increase in the age of the population. Today in Argentina, the elderly man (AM: person aged 65 years or older) has a life expectancy of 76 years and women 80 years, which represents 15% of the percentage of the population in large urban centers.…”

“…Revista de la Sociedad Argentina de Diabetes Año 58 Vol. 58 Nº 1 Suplemento Recomendaciones de los Comités de Trabajo Enero-abril de 2024:[28][29][30][31][32] ISSN 0325-5247 (impresa) ISSN 2346-9420 (en línea) Comité de Gerontología. Abordaje clínico terapéutico del adulto mayor con diabetes mellitus/ Recomendaciones…”